# Cipla share price today (Cipla Ltd, NSE: CIPLA)

> Cipla share price today: ₹1,396.90 at the NSE close on 3 November 2026, down 7.0% in a year. Cipla (NSE: CIPLA) is worth ₹1,12,843 crore, trades at a P/E of 36.4 and has closed between ₹1,192.40 and ₹1,532.10 over the past 52 weeks. > Cipla Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. CIPLA · Pharma - Formulators · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/cipla-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from the last 12 quarters
- Price: ₹1,396.90 (−7.0% in a year)
- P/E: 36.4× (higher than 80% of the last 11 years)
- Revenue (Sep 2026): ₹7,404 Cr (−2.4% on a year ago)
- Profit (Sep 2026): ₹852 Cr (−37.0% on a year ago)
- Operating margin: 19.0% (−6.0 points on a year ago)
- ROCE: 15%, FY26
- ROIC: 10.2%, against a 12.0% cost of capital: −1.8 points

The main question: domestic institutions moved +10.7 percentage points over 8 quarters while the business went the other way. ## What is the Cipla share price today? Cipla Ltd's share price was ₹1,396.90 at the close on 3 November 2026. It has been falling for 3 weeks. That is 0.2% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,192 and ₹1,532, and at that close it sat 60% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 3 weeks in a row. Over the last 11 years the share price moved +161% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Cipla this quarter? Three changes stood out: indian funds and insurers (DIIs) raised their stake for 8 quarters in a row, profit down on a year earlier for 4 quarters in a row and operating margin down 6 points on a year earlier. 1. Indian funds and insurers (DIIs) raised their stake for 8 quarters in a row From 24% to 34.6% of the company by the September 2026 quarter. 2. Profit down on a year earlier for 4 quarters in a row In the September 2026 quarter profit was ₹852 crore, -37% on a year earlier. Why: Profit fell because a key US medicine resupply is not coming back this year. That takes away a way for the US business to recover soon. Next results: check for a clear FDA update on Lanreotide and whether it comes back. From the earnings call on 27 Oct 2026. 3. Operating margin down 6 points on a year earlier 19% in the September 2026 quarter, from 25%. Why: Margin fell because the company spent more on planned launches and getting factories ready. Next results: check whether sales from the North American business help the margin recover. From the earnings call on 27 Oct 2026. ## What are Cipla's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Cipla reported revenue of ₹7,404 crore, down 2.4% from ₹7,589 crore a year earlier, and a profit of ₹852 crore, down 37.0% from ₹1,353 crore. ### Cipla results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹7,404 crore | ₹7,589 crore | −2.4% |
| Profit | ₹852 crore | ₹1,353 crore | −37.0% |
| Earnings per share | ₹10.86 | ₹16.73 | −35.1% |
| Operating margin | 19.0% | 25.0% | −6.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Cipla's management discussed these results on a call held on 27 October 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Cipla share price history? Cipla closed at ₹1,396.90 on 3 November 2026, down 7.0% from ₹1,501.30 a year earlier (31 October 2025) and up 53.4% over five years. Its highest weekly close since March 2016 was ₹1,672.50 on 27 September 2024. ### Cipla share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹1,338.00 | +4.4% |
| 1 month ago · 1 Oct 2026 | ₹1,344.00 | +3.9% |
| 6 months ago · 30 Apr 2026 | ₹1,309.60 | +6.7% |
| 1 year ago · 31 Oct 2025 | ₹1,501.30 | −7.0% |
| 3 years ago · 3 Nov 2023 | ₹1,206.35 | +15.8% |
| 5 years ago · 4 Nov 2021 | ₹910.70 | +53.4% |
| 10 years ago · 4 Nov 2016 | ₹544.70 | +156.5% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹534.60 | +161.3% |
| Highest weekly close since March 2016 · 27 Sep 2024 | ₹1,672.50 | −16.5% |
| Lowest weekly close since March 2016 · 20 Mar 2020 | ₹392.80 | +255.6% |
| 52-week high (weekly close) · 14 Nov 2025 | ₹1,532.10 | −8.8% |
| 52-week low (weekly close) · 2 Apr 2026 | ₹1,192.40 | +17.2% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (563 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Cipla? 3 Nov 2026: Cipla closed at ₹1,396.90, up 4.4% on the week and up 3.9% on the month. 27 Oct 2026: Cipla held its results call for July to September 2026. Management guided: FY27 US exit run rate of $1 billion annualized, excluding Lanreotide, which is not expected to return this fiscal year. ### Earlier

- Results for July to September 2026: Revenue down 2.4% and profit down 37.0% on a year earlier. - 5 Jun 2026: ex-date for a dividend of ₹13 a share. ## What dividend does Cipla pay? Cipla paid ₹13 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.93% at the ₹1,396.90 close on 3 November 2026. The last was a dividend of ₹13 a share, ex-date 5 June 2026. ### Cipla dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 5 Jun 2026 | ₹13 | Dividend | same day |
| 27 Jun 2025 | ₹16 | Dividend + Special | same day |
| 2 Aug 2024 | ₹13 | Dividend | same day |
| 21 Jul 2023 | ₹8.50 | Dividend | same day |
| 8 Aug 2022 | ₹5 | Dividend | 10 Aug 2022 |
| 9 Aug 2021 | ₹5 | Dividend | n/a |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Cipla Ltd paid out 27% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Cipla management say on the latest results call? On the call for July to September 2026, held on 27 October 2026, Cipla's management guided: FY27 US exit run rate of $1 billion annualized, excluding Lanreotide, which is not expected to return this fiscal year. > “All of these are complex assets. We do not have plain-vanilla generics in the pipeline.”
> Achin Gupta, on the call for July to September 2026

### What management guided

- FY27 operating margin of 18.5%-20%, with sequential improvement expected in each remaining quarter. - Generic Advair launch in Q3, with revenues building through Q3 and Q4. - Three further significant US launches (two respiratory, one peptide) expected in FY27; 45-50 North American filings over 3 years and pembrolizumab filing next year. - FY27 R&D expense of 6%-7% of revenue. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/59/Conference Call/CC-Oct26.pdf). (From the call for July to September 2026, 27 October 2026.)

## What to watch in Cipla's next results? When Cipla reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Ventolin supply ramp at the North American facility; check for stronger sales as manufacturing scales. - What to check (from the call)
- Ventolin supply ramp at the North American facility; check for stronger sales as manufacturing scales. - Advair launch and early revenue build; check whether commercialization follows the stated timetable. - Lanreotide remediation and new-site filing; look for a concrete FDA resupply or filing update. - Pithampur remediation; check for a regulatory classification update and progress toward resolving observations. ## Which stock lists is Cipla on? Cipla is on 2 of our India lists: Nifty 50 companies and Pharma stocks. - [Nifty 50 companies](https://www.sectoralpha.in/nifty-50-stocks-list)
- [Pharma stocks Market value (₹ crore): 112051.37355863368](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Cipla profitable? Cipla Ltd earned ₹852 Cr of net profit in the Sep 2026 quarter, −37.0% on the same quarter a year earlier. Full-year FY26 profit was ₹3,862 Cr. Over 10 years profit has grown 10.8% a year on average. That is 11.5% of the quarter's revenue. The same quarter a year earlier earned ₹1,353 Cr. For the full year, FY26 profit was ₹3,862 Cr (−26.7% on the year before). Why profit moved: revenue changed −2.4% on a year earlier and the margin moved −6.0 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed −47.2% and revenue −0.7%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Cipla make, and is it growing? Cipla Ltd reported ₹7,404 Cr of revenue in the Sep 2026 quarter, −2.4% on the same quarter a year earlier. Over 10 years it has grown 7.4% a year on average. The last full year, FY26, came in at ₹28,163 Cr. The last four reported quarters add to ₹28,138 Cr. FY26 revenue was ₹28,163 Cr, +2.2% on the year before. Recent pace: the last four quarters grew −0.7% on average, against 7.4% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −0.7%, against +3.0% a year over the last 8 quarters (rolling over); profit over the last 12 months grew −47.5%, against −20.2% a year (rolling over). ## How much of every ₹100 of sales does Cipla keep? Cipla Ltd's operating margin was 19.0% in the Sep 2026 quarter, 6.0 percentage points lower than the same quarter a year ago. Across 13 years it has been between 17.0% and 26.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −6.2 percentage points on the year while gross margin changed −2.7 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Cipla's profit turning into cash? Over the last 3 years, 98% of Cipla Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹3,940 Cr of operating cash against ₹3,862 Cr of profit. After ₹4,115 Cr of spending on assets, free cash was −₹175 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 98% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle. What to look at next: the bigger use of cash is spending on new assets, at 2.3× depreciation over three years. The next section checks what that spending is building. ## Where does Cipla's cash go? Cipla Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 202 days in FY26, up from 195 days in FY21. It spent ₹7,592 Cr on assets over the last 3 years. Customers take 73 days to pay, and stock sits for 252 days on average. At FY26 sales of ₹28,163 Cr, each day of that cycle ties up about ₹77.2 Cr, so roughly ₹15,586 Cr is tied up in the business at any time. FY26: customers took 73 days to pay and stock sat for 252 days, about 8.3 months of sales sitting as stock, for a full cycle of 202 days, longer than FY21's 195. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 252 days. Customers pay about 73 days after that. Suppliers are paid at 123 days. Together that makes the 202-day cycle. Spending on assets: ₹7,592 Cr over the last 3 years, against ₹3,369 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹2,042 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Cipla's P/E ratio, and how does it compare with its own history? Cipla Ltd's P/E is 36.4×, near the high end of its own history: higher than 80% of past readings. Its usual P/E (the middle reading) is 29.8×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹35.87. Why the multiple is where it is: over the past year earnings per share moved −26.4% while the price moved −7.0%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +8.9% a year; about +3.0% a year came from earnings growth and about +5.9 percentage points from the multiple (the market paying more); over 10 years the price moved +9.9% a year; about +13.4% a year came from earnings growth and about −3.5 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Cipla business getting better or worse? Cipla Ltd's business is getting worse. Revenue, profit and EPS growth are shrinking: revenue growth is −0.7% in the latest quarter, against +14.4% at its best in 12 quarters, with ROCE falling at 11.1%. This is based on 12 quarters of 4 measures. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. ## How much does Cipla earn on its capital? Cipla Ltd earned a ROCE of 15% in FY26. That is up from a low of 7% in FY17. Its return on capital used (ROIC) is 1.8 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 13.7% net margin and 0.67× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 13.7% net margin × 0.67× asset turnover × 1.23× leverage (assets divided by equity) ≈ 11.3% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 10.2% − 12.0% = −1.8 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 10.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 15.5%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Cipla have too much debt? Cipla Ltd has total debt of ₹699 Cr against shareholder equity of ₹35,522 Cr as of Sep 2026, so its debt is 0.02× its equity, which is very little. Year by year, that ratio went from 0.05 in FY22 to 0.02 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Cipla shareholding pattern? Domestic institutions raised their stake in Cipla Ltd by 10.7 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 34.6% of the company. Foreign institutions moved −8.6 points over the same period, to 20.2%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: +10.7 points over 8 quarters, to 34.6%; Foreign institutions: −8.6 points over 8 quarters, to 20.2%; Promoters: −1.7 points over 8 quarters, to 29.2%. Why the owners changed: foreign institutions moved −8.6 points and domestic institutions +10.7 points over 8 quarters, while promoters moved −1.7 points. One group of institutions took over shares from the other; it is not a change of mind by the people running the company. ## How far is Cipla from balance-sheet trouble? For Cipla Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Cipla rank in its industry? 35.4 out of 100, rank 37 of 44 in Pharma - Formulators, with 100% of the evidence available. Cipla Ltd scores 35.4 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 37. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 4.5 + 12.6 + 11.2 + 7.1 = 35.4. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Cipla compared with? Cipla ranks 37 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 35.4 out of 100. 1. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · leader · Most evidence points up · 83% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 46.8% · Profit 91.4% · Operating margin change 2 points · 88% evidence Capital efficiency 18.6/25 · ROCE 28.4% · Operating margin 24% · 100% evidence Valuation 6.2/20 · P/E 92.5× · PEG 2.31 · 65% evidence Relative strength 16.5/20 · Lead over its industry 28.1% · Lead over NIFTY 500 53.6% · 1 year 160.5% · 70% evidence · 11 of 12 weeks ahead Exact sum: 30.1 + 18.6 + 6.2 + 16.5 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 81% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.9/35 · Revenue 37.9% · Profit 88.4% · Operating margin change 3 points · 88% evidence Capital efficiency 18.2/25 · ROCE 24.1% · Operating margin 25% · 100% evidence Valuation 11.0/20 · P/E 44.2× · PEG 0.54 · 100% evidence Relative strength 12.3/20 · Lead over its industry n/a · Lead over NIFTY 500 74.4% · 1 year 288.9% · 25% evidence · 9 of 9 weeks ahead Exact sum: 29.9 + 18.2 + 11 + 12.3 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · leader · Most evidence points up · 65% evidence 70.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.4/25 · ROCE 24.9% · Operating margin 24% · 100% evidence Valuation 9.1/20 · P/E 26.9× · PEG n/a · 50% evidence Relative strength 18.6/20 · Lead over its industry 21.4% · Lead over NIFTY 500 47.6% · 1 year 132.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.4 + 21.4 + 9.1 + 18.6 = 70.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · leader · Most evidence points up · 100% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.3/25 · ROCE 34.5% · Operating margin 31% · 100% evidence Valuation 7.1/20 · P/E 34.7× · PEG 1.77 · 100% evidence Relative strength 10.5/20 · Lead over its industry -3.5% · Lead over NIFTY 500 20% · 1 year 42.3% · 100% evidence · 11 of 12 weeks ahead Exact sum: 30.3 + 21.3 + 7.1 + 10.5 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Most evidence points up · 86% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 32.9% · Profit 100% · Operating margin change 2 points · 88% evidence Capital efficiency 20.3/25 · ROCE 39.8% · Operating margin 20% · 100% evidence Valuation 11.2/20 · P/E 20.8× · PEG n/a · 50% evidence Relative strength 8.6/20 · Lead over its industry -11.4% · Lead over NIFTY 500 10.8% · 1 year 21.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 29.1 + 20.3 + 11.2 + 8.6 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 67.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.3/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.7/25 · ROCE 16.9% · Operating margin 26% · 76% evidence Valuation 6.4/20 · P/E 42.4× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 59% · Lead over NIFTY 500 86.2% · 1 year 312.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.3 + 14.7 + 6.4 + 16.7 = 67.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · breaking out · Most evidence points up · 76% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.9/43.75 · Revenue 50.3% · Profit 91.3% · Operating margin change 0 points · 88% evidence Capital efficiency 19.0/31.25 · ROCE 21.5% · Operating margin 14% · 100% evidence Valuation 14.9/25 · P/E 52.7× · PEG 0.77 · 100% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.9 + 19 + 14.9 = 65.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 8. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Most evidence points up · 89% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.9/35 · Revenue 28.2% · Profit 49.2% · Operating margin change 2 points · 88% evidence Capital efficiency 19.4/25 · ROCE 29.9% · Operating margin 30% · 100% evidence Valuation 16.1/20 · P/E 15.4× · PEG 0.54 · 65% evidence Relative strength 2.0/20 · Lead over its industry -24.5% · Lead over NIFTY 500 -4.7% · 1 year 2.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.9 + 19.4 + 16.1 + 2 = 65.4 · What this means: Earnings are strong; relative strength in its sector is -24.5% and the one-year return is 2.4%. 9. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · turning · Most evidence points up · 78% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 10.6% · Profit 68% · Operating margin change 6 points · 83% evidence Capital efficiency 15.7/25 · ROCE 17% · Operating margin 24% · 76% evidence Valuation 11.0/20 · P/E 35.6× · PEG n/a · 50% evidence Relative strength 14.7/20 · Lead over its industry -0.5% · Lead over NIFTY 500 23.6% · 1 year 51.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24 + 15.7 + 11 + 14.7 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · leader · Evidence leans up · 74% evidence 64.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 19.6% · Profit 48% · Operating margin change 9 points · 88% evidence Capital efficiency 17.2/25 · ROCE 18.8% · Operating margin 25% · 100% evidence Valuation 6.3/20 · P/E 26.8× · PEG 2.85 · 65% evidence Relative strength 11.9/20 · Lead over its industry n/a · Lead over NIFTY 500 40.1% · 1 year 68.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 28.7 + 17.2 + 6.3 + 11.9 = 64.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 11. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · basing · Evidence leans up · 85% evidence 62.8 out of 100 Growth Capital Valuation Relative
12. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · turning · Evidence leans up · 73% evidence 62.5 out of 100 Growth Capital Valuation Relative
13. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · losing its lead · Evidence leans up · 71% evidence 61.8 out of 100 Growth Capital Valuation Relative
14. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Evidence leans up · 100% evidence 61.0 out of 100 Growth Capital Valuation Relative
15. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · leader · Evidence leans up · 96% evidence 58.1 out of 100 Growth Capital Valuation Relative
16. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 71% evidence 56.2 out of 100 Growth Capital Valuation Relative
17. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.1 out of 100 Growth Capital Valuation Relative
18. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 75% evidence 55.3 out of 100 Growth Capital Valuation Relative
19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · losing its lead · Evidence leans up · 96% evidence 54.3 out of 100 Growth Capital Valuation Relative
20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 71% evidence 52.8 out of 100 Growth Capital Valuation Relative
21. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · breaking out · Evidence leans up · 78% evidence 51.3 out of 100 Growth Capital Valuation Relative
22. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · leader · Evidence leans up · 71% evidence 50.9 out of 100 Growth Capital Valuation Relative
23. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 78% evidence 47.6 out of 100 Growth Capital Valuation Relative
24. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · turning · Evidence leans down · 81% evidence 46.9 out of 100 Growth Capital Valuation Relative
25. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · quiet · Evidence leans down · 100% evidence 46.5 out of 100 Growth Capital Valuation Relative
26. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 100% evidence 46.0 out of 100 Growth Capital Valuation Relative
27. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.9 out of 100 Growth Capital Valuation Relative
28. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans down · 96% evidence 45.7 out of 100 Growth Capital Valuation Relative
29. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · turning · Evidence leans down · 96% evidence 44.9 out of 100 Growth Capital Valuation Relative
30. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 100% evidence 43.1 out of 100 Growth Capital Valuation Relative
31. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 42.6 out of 100 Growth Capital Valuation Relative
32. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 71% evidence 42.2 out of 100 Growth Capital Valuation Relative
33. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
34. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · turning · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
35. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Evidence leans down · 96% evidence 38.8 out of 100 Growth Capital Valuation Relative
36. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 74% evidence 35.8 out of 100 Growth Capital Valuation Relative
37. Cipla Ltd this page CIPLA · turning · Evidence leans down · 100% evidence 35.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 4.5/35 · Revenue -0.7% · Profit -47.5% · Operating margin change -6 points · 100% evidence Capital efficiency 12.6/25 · ROCE 15.5% · Operating margin 19% · 100% evidence Valuation 11.2/20 · P/E 35.9× · PEG 1.25 · 100% evidence Relative strength 7.1/20 · Lead over its industry -17.6% · Lead over NIFTY 500 4.1% · 1 year -8.2% · 100% evidence · 1 of 12 weeks ahead Exact sum: 4.5 + 12.6 + 11.2 + 7.1 = 35.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · losing its lead · Most evidence points down · 100% evidence 34.6 out of 100 Growth Capital Valuation Relative
39. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · quiet · Most evidence points down · 96% evidence 34.4 out of 100 Growth Capital Valuation Relative
40. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
41. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Too little evidence to rank firmly · 42% evidence 49.7 out of 100 Growth Capital Valuation Relative
42. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.3 out of 100 Growth Capital Valuation Relative
43. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · losing its lead · Too little evidence to rank firmly · 49% evidence 38.4 out of 100 Growth Capital Valuation Relative
44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · turning · Too little evidence to rank firmly · 31% evidence 36.7 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to Cipla in size? Cipla is the 5th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Torrent Pharmaceuticals, Zydus Lifesciences and Dr Reddys Laboratories. Just below it: Mankind Pharma, Aurobindo Pharma and Lupin. ### Pharma - Formulators companies close in size

1. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) ₹1,75,479 crore
2. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ₹1,24,239 crore
3. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) ₹1,12,849 crore
4. Cipla Ltd ₹1,11,397 crore
5. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) ₹1,02,964 crore
6. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) ₹96,744 crore
7. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) ₹91,962 crore

[All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies)

### Companies close in size in other industries

1. [LG Electronics India Ltd](https://www.sectoralpha.in/stocks/lg-electronics-india-ltd) ₹1,12,771 crore · Consumer Electronics
2. [Britannia Industries Ltd](https://www.sectoralpha.in/stocks/britannia-industries-ltd) ₹1,11,763 crore · FMCG - Foods
3. Cipla Ltd ₹1,11,397 crore
4. [GAIL (India) Ltd](https://www.sectoralpha.in/stocks/gail-indialtd) ₹1,10,402 crore · Gas Distribution
5. [Tata Power Company Ltd](https://www.sectoralpha.in/stocks/tata-power-company-ltd) ₹1,10,255 crore · Power - Generation/Distribution

## What else do people ask about Cipla? ### What is Cipla's share price today? Cipla Ltd's share price is ₹1,396.90, −7.0% over the past year. The whole company is worth ₹1,12,843 Cr on the market. In the last 52 weeks it traded between ₹1,192 to ₹1,532; today it is 60% of the way up from the low, 0.2% above its 200-day average (as of 3 November 2026). ### What were Cipla's latest quarterly results? Cipla Ltd reported revenue of ₹7,404 Cr and net profit of ₹852 Cr for the Sep 2026 quarter. Revenue fell 2.4% and profit fell 37.0% compared with a year earlier. Earnings per share were ₹10.86. The operating margin was 19.0%, 6.0 percentage points lower than a year earlier (as of 3 November 2026). ### What is Cipla's market cap? Cipla Ltd's market capitalisation is ₹1,12,843 Cr at a share price of ₹1,396.90. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Cipla performing? Cipla Ltd's share price has been falling for 3 weeks. In its latest quarter, revenue fell 2.4% and profit fell 37.0% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 3 weeks running (as of 3 November 2026). ### Will Cipla's share price go up? This page does not forecast Cipla Ltd's share price. What it shows instead: the share price is ₹1,396.90, and it has been falling for 3 weeks. Its P/E of 36.4× is higher than 80% of its own last 11 years (as of 3 November 2026). ### Does Cipla have too much debt? No, Cipla Ltd has little debt: its debt is 0.02× its equity, and its operating profit is more than 100 times its interest bill. FY26 borrowings were ₹614 Cr against equity of ₹34,432 Cr. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is Cipla in its business cycle? Cipla Ltd's FY26 operating margin was 21.0%, against a 13-year range of 17.0% to 26.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 19.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Cipla story? The main question: domestic institutions moved +10.7 percentage points over 8 quarters while the business went the other way. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Cipla a stock worth studying right now? What the numbers show: Cipla Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether the owners’ moves turn back in line with the business. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Cipla share price forecast for 2026? What management itself guided: FY27 US exit run rate of $1 billion annualized, excluding Lanreotide, which is not expected to return this fiscal year. ## Lists

- Nifty 50 companies: https://www.sectoralpha.in/nifty-50-stocks-list
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.